2Mason JJ,Williams BO. SOST and DKK:antagonists of LRP family signaling as targets for treating bone disease[J].J Osteoporos ,2010 ;4:601-20.
3Gimble JM, Zvonie S, Floyd ZE, et al. Playing with bone and fat[J]. J Cell Biochem,2006;98(2) :251-66.
4Liu LF,Shen WJ ,Zhang ZH,et al. Adipocytes decrease Runx2 expression in osteoblastic cells : roles of PPARγ and adiponectin [ J ]. J Cell Physiol, 2010 ;225 (3) :837-45.
5Rao TP Ktihl M. An updated overview on wnt signaling pathways:a prelude for more[J]. Circ Res,2010;106:1798-806.
6Gong Y, Bourhis E, Chiu C, et al. Wnt isoform-specifie interactions with eoreceptor specify inhibition or potentiation of signaling by LRP6 antibodies[J]. Plos One,2010;5(9) :12682.
7Green JL, Kuntz SG ,Steinberg PW. Ror receptor tyrosine kinases :orphans no more [J].Trends Cell Biol,2008 ; 18 ( 11 ) :536"44.
8Glass DA, Karsenty G. In vivo analysis of Wnt signaling in bone [J]. Endocrinology ,2007 ; 148 (6) :2630-4.
9Rodriguez-Carballo E, Ulsamer A, Susperregui AR,et al. Conserved regu- latory motifs in osteogenie gene promoters integrate cooperative effects of canonical wnt and BMP pathways [ J ]. J Bone Miner Res,2010 (Epub ahead of print).
10MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: component, mechanisms, and diseases[J]. Dev Cell ,2009 ; 17 ( 1 ) :9-26.
